Amit Bar-Or MD
Neuroimmunology/Multiple Sclerosis
Director, Center for Neuroinflammation and Neurotherapeutics Chief, Multiple Sclerosis Division
Join to View Full Profile
3400 Civic Center BoulevardPhiladelphia, PA 19104
Phone+1 215-220-9384
Dr. Bar-Or is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Harvard Medical SchoolImmunology, 1997 - 2000
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1993 - 1997
McGill University Faculty of MedicineClass of 1993
Certifications & Licensure
PA State Medical License 2016 - 2026
MA State Medical License 1997 - 2001
Clinical Trials
- Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis Start of enrollment: 2017 Oct 19
- COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders Start of enrollment: 2021 Aug 13
- Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) Start of enrollment: 2019 Dec 19
Publications & Presentations
PubMed
- Safety and tolerability of conversion to siponimod from other disease-modifying therapies in patients with advancing forms of relapsing MS: Results from the EXCHANGE s...Robert J Fox, Stanley Cohan, Yang Mao-Draayer, Bianca Weinstock-Guttman, Linda-Ali Cruz
Multiple Sclerosis. 2025-04-18 - Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMS.Douglas L Arnold, Shannon Kolind, Haz-Edine Assemlal, Amit Bar-Or, Matilde Inglese
Multiple Sclerosis. 2025-04-16 - Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis.Robert J Fox, Amit Bar-Or, Anthony Traboulsee, Celia Oreja-Guevara, Gavin Giovannoni
The New England Journal of Medicine. 2025-04-08
Journal Articles
- Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients with Relapsing-Remitting Multiple SclerosisMyla D Goldman, Amit Bar-Or, JAMA Neurology
- Ofatumumab Versus Teriflunomide in Multiple SclerosisStephen L Hauser, Amit Bar-Or, Patricia K Coyle, Alexandra Goodyear, The New England Journal of Medicine
Authored Content
- Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients with Relapsing-Remitting Multiple SclerosisAugust 2020
- Ofatumumab Versus Teriflunomide in Multiple SclerosisAugust 2020
- Ofatumumab Versus Teriflunomide in Multiple SclerosisAugust 2020
Press Mentions
MS Activity Remains Low on Long-Term FenebrutinibMarch 27th, 2025- Paramagnetic Rim Lesions May Aid MS Diagnosis and TreatmentMarch 3rd, 2025
- B Cells Drive Responses of Other Immune Cells, and Can Be Modified to Prevent Multiple Sclerosis SymptomsMay 3rd, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
